Abstract YO27
Case summary
Whole Brain Radiotherapy plays a pivoted role in brain metastases. There is controversy regarding the radiotherapeutics dose fractionation in brain metastasis. 30 Gray in 10 fractions in 2 weeks in the standard regimen in most centers. Regarding the extraordinary poor survival prognosis of patients with brain metastasis, 20 Gray in 5 fractions over 1 week would be preferable. An observational comparative analytical study was conducted in National Academy of Medical Sciences (NAMS) Bir Hospital after ethical approval from the institutional review board of NAMS. Patients were randomized into two group one with 20 Gray in 5 fraction over one week and other with the 30Gray in 10 Fraction over 2 weeks. A total number of 55 patients were enrolled in the study. Assessment of clinical symptoms was done using Common terminology Criteria for Adverse Events (CTCAE), before treatment, just after treatment and 6 weeks of treatment. Response evaluation criteria in solid tumors (RECIST) was used to access the treatment response in terms of local control. Acute toxicity of the patients were assess during treatment and then followed for 6 weeks and graded according to Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring. Of the 55 patients enrolled, in 20Gray/5# (n=28) and 30Gray/10# (n=26) groups, all participants in the study received the planned treatment of radiotherapy. Local control with complete or partial response was 63% in 20Gray v 48% in 30Gray (p = 0.722). Six month survival was 29.1% in 20Gray/5# v 23.6% in 30Gray/10# (p = 0.504). Objective Responsive of Headache was 53% v 52% (p= 0.469), vomiting 43% v 55%,(p=0.956),Seizure 11.7% v 3.7% (p = 0.979), focal weakness 21.3% v 4.4% (p=0.249), ataxia1 4.3% v 3.7% (p=0.281), speech disorder 3.5% v 7.4% (p=0.147), acute toxicities of grade 2 and grade 3 were acceptable in both Groups, nausea 9.1% v 9.1% ( p =0.907), vomiting 1.9% v 3.7% (p=0.199) , headache 1.9% v 3.7% (p=0.696) and Dermatitis 5.7% v 5.7% (p =0.140) 20Gray in 5fractions and 30Gray in 10 Fractions are equally effective and feasible as statistically insignificant difference in the response rate and acute toxicities were observed in the two groups
Clinical trial identification
Editorial acknowledgement
Resources from the same session
411P - Comparative analysis of protein profiles of prognosis-associated proteins and KIT-related proteins in gastrointestinal stromal tumour
Presenter: Yoshiyuki Suehara
Session: Poster display session
Resources:
Abstract
412P - The evaluation of chromosomal changes in patients with osteosarcoma
Presenter: Nargiza Karimova
Session: Poster display session
Resources:
Abstract
413P - The state of molecular biological markers in osteosarcoma
Presenter: Djamilya Polatova
Session: Poster display session
Resources:
Abstract
414P - Clinical profile of gastrointestinal stromal tumour in Yangon General Hospital
Presenter: Khin Mu
Session: Poster display session
Resources:
Abstract
415P - Adult soft tissue myoepithelial carcinoma: Treatment outcomes and efficacy of chemotherapy
Presenter: Florence Chamberlain
Session: Poster display session
Resources:
Abstract
417P - Clinicopathological profile and survival outcomes of sarcomas from a regional cancer centre in South India
Presenter: Divya Bharathi
Session: Poster display session
Resources:
Abstract
418P - Lessons learnt from treatment of foot sarcomas: Analysis from dedicated sarcoma clinic in North India
Presenter: Satyajit Pawar
Session: Poster display session
Resources:
Abstract
423P - Effectiveness of first-generation 5HT3 receptor antagonist plus dexamethasone plus aprepitant in controlling delayed chemotherapy-induced nausea and vomiting in patients with colorectal cancer: A propensity score-matched analysis
Presenter: Toshinobu Hayashi
Session: Poster display session
Resources:
Abstract
424P - Cancer worry, genetic knowledge, and attitudes towards NGS multigene panel testing among Korean breast cancer patients
Presenter: Ji Soo Park
Session: Poster display session
Resources:
Abstract
425P - Economic and safety evaluation of 5-HT3 recepter antagonist conversion from palonosetron to granisetron in highly and moderately emetogenic chemotherapy: A prospective study
Presenter: Keisuke Yamakita
Session: Poster display session
Resources:
Abstract